Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Medicare Rx “Debit Card” Will Fund $5 Bil. In Drug Purchases, CMS Estimates

  • News

Executive Summary

The Medicare discount card program will provide $2.4 bil. in federal funds to support drug purchases by low-income seniors during 2004, CMS estimates

You may also be interested in...



Merck Offers Free Drugs To Medicare Rx Debit Card Enrollees

Merck will offer its drugs free to low-income seniors who sign up for Medicare-endorsed discount cards, the company announced Feb. 12

Merck Offers Free Drugs To Medicare Rx Debit Card Enrollees

Merck will offer its drugs free to low-income seniors who sign up for Medicare-endorsed discount cards, the company announced Feb. 12

Medicare Card Plan Is “Loss Leader” For 2006, Ex-CMS Head Scully Says

Sixty-five companies have applied to sponsor a Medicare-endorsed "debit" card in 2004, former Centers for Medicare & Medicaid Services Administrator Tom Scully said Jan. 14 during a Lash Group/Medical Marketing Economics conference in Washington, D.C

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS043035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By